Dr. Jeremy Harris
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Studies Lung Cancer
Studies Cancer
7 reported clinical trials
13 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage I
Stage II
2Cancer
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Jeremy Harris is currently running
Surgical Excision Margins
for Melanoma
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.
Recruiting1 award N/A9 criteria
Radiation Therapy + Atezolizumab
for Small Cell Lung Cancer
This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
Recruiting1 award Phase 2 & 311 criteria
More about Jeremy Harris
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jeremy Harris has experience with
- Radiation Therapy
- Atezolizumab
- Stereotactic Body Radiation Therapy
- Irreversible Electroporation (IRE) Ablation
- Wide Local Excision = 1cm Margin
- Wide Local Excision = 2cm Margin
Breakdown of trials Jeremy Harris has run
Lung Cancer
Soft Tissue Sarcoma
Small Cell Lung Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeremy Harris specialize in?
Jeremy Harris focuses on Lung Cancer and Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage I.
Is Jeremy Harris currently recruiting for clinical trials?
Yes, Jeremy Harris is currently recruiting for 2 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Jeremy Harris has studied deeply?
Yes, Jeremy Harris has studied treatments such as Radiation Therapy, Atezolizumab, Stereotactic Body Radiation Therapy.
What is the best way to schedule an appointment with Jeremy Harris?
Apply for one of the trials that Jeremy Harris is conducting.
What is the office address of Jeremy Harris?
The office of Jeremy Harris is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.